SCHEMBL10230626

SCHEMBL10230626

CCC(N)c1cccc(-c2cc(-c3nc(-c4ccc(=O)n(C(CC)CC)c4)cnc3N)on2)c1

nearest known ligand 0.75

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ATR Q13535 20/20 0.75
ATM Q13315 4/20 0.48
GSK3B P49841 1/20 0.48
PRKDC P78527 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10231258 0.95 ATR (0.73) ATRATMGSK3BPRKDC
SCHEMBL10228677 0.94 ATR (0.74) ATRATMGSK3BPRKDC
SCHEMBL10228722 0.88 ATR (0.74) ATRATMGSK3BPRKDC
SCHEMBL10177956 0.86 ATR (0.56) ATR
SCHEMBL10230604 0.86 ATR (0.73) ATRATMGSK3BPRKDC
SCHEMBL10230630 0.85 ATR (1.00) ATRATMGSK3BPRKDC
SCHEMBL10231215 0.84 ATR (0.67) ATRATMGSK3BPRKDC
SCHEMBL10231213 0.82 ATR (0.75) ATRATMGSK3BPRKDC
SCHEMBL10230586 0.82 ATR (0.63) ATRATMGSK3BPRKDC
SCHEMBL18774332 0.82 ATR (0.65) ATRATMGSK3BPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885ATM 32/4885GSK3B 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.